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From the
President

The functional
planning
continues as we await state approval of
our Certificate of Need (CON) for a
52-bed skilled nursing facility. Plans
to renovate our GI Lab have been
cleared at the state level, and
remodeling is anticipated to begin in
the near future. Also, 7C has been
remodeled and is now our Nephrology
Unit. At 17th & Chew, 5T and 4T
have closed, while 4S has become a
36-bed patient care unit.
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Several important searches continue.
The Chief of Surgery search continues,
and we all hope for positive news
shortly. A search is well underway for
the Chief Operating Officer. Several
excellent candidates have been
interviewed, and the committee will be
meeting again within the next several
weeks to discuss these candidates.
Elliot Sussman, M.D., has asked me to
chair a committee to search for the
Chief of Clinical Services. Our first
meeting will be held within the next
few weeks, and, hopefully, we will
have candidates to interview shortly
thereafter.
As a reminder, the Physician
Assistance Program is continuing its
confidential professional counseling
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services to active members of the
Medical Staff and their dependents.
This program offers physicians and
families counseling services for a wide
range of personal problems, and is of a
strictly confidential nature and easy to
use. The number is 433-8550 or 1800-327-8878, requiring only the
identification as a. member of Lehigh
Valley Hospital medical staff or a
family member, and ask to speak to the
Program Manager, Oliver Neith.
Also, for the past two years, our
Physician Well-Being group has met
every other week from 6 to 7:30p.m.
All meetings are held in the
Conference Dining Room at Cedar
Crest & I-78. If anyone has questions
or needs information, please contact
John Turoczi, EdD, Group Facilitator,
at (610) 481-9161.
Finally, on a sad note, we all extend
our sympathies to Russ Rentler for the
recent loss of his wife, Susan. Anyone
wishing to contribute to a fund to help
Russ obtain the services of a nanny for
his young children may contact the
Medical Staff Office at 402-8900.
Best wishes to all,

A. Candio
dent, Medical Staff

Laboratory Update
Handy Reference
Health Network Laboratories is structured to assure that most
technical or logistical questions can be handled by the supervisor of the division in
question. However, if you ever have a question that requires further clarification,
a technical director is available to assist you.
Listed below is a handy reference of those individuals technically responsible for
the various divisions of the laboratory.

Division

Technical Director

Supervisor

Microbiology/
Virology

David G. Beckwith, Ph.D.
402-8157

Georgia Colasante
402-8196

Immunology
Flow Cytometry

David G. Beckwith, Ph.D.
402-8157
Gerald E. Clement, Ph.D.
402-8156 or 402-2534

Gale Fritch
402-2845

HLA Laboratory

Bala B. Carver, M.D.

Marjorie Williams
402-8016

402-8142 or 402-2571
Blood Bank

Bala B. Carver, M.D.
402-8142 or 402-2571

Kathleen Mundt
402-8180

Hematology
Coagulation

David Prager, M.D.
433-6691

Dolores Benner
402-8177

Toxicology
Endocrinology

Gerald E. Clement, Ph.D.
402-8156 or 402-2534

Joann Sell
402-2578

Chemistry

Gerald E. Clement, Ph.D.
402-8156 or 402-2534

Jan Gushen
402-8043

Cytology

William Dupree, M.D.
402-2551

Linda Pflueger
402-2835

General laboratory concerns can be handled by David G. Beckwith, Ph.D.,
Administrator and Clinical Director, at 402-8150 or John J. Shane, M.D.,
Chairman, Department of Pathology, at 402-8152.
Continued on Page 3
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Laboratory Newsletter
In an effort to provide you with timely
infonnation regarding laboratoryrelated issues, beginning this month,
Medical Sttif/ Progress Notes will
regularly include a brief newsletter
published by Health Network

Laboratories. This month's newsletter
can be found on pages 25-27. If you
have any questions or ideas for future
topics, please contact Gerald E.
Clement, Ph.D., Director, Chemistry,
at 402-2534.

Consolidation Moves
On March 2, the 4S Nephrology unit
began transitioning to the newly
renovated 7C wing at Cedar Crest &
1-78. The new telephone number for
the unit is 402-1900. Simultaneously,
the 5T medical/surgical unit was
closed, and the 4T occupancy increased
to 36 patients.

With 4T remaining as the only
medical/surgical unit, medical patient
admissions will need to be directed to
the appropriate sites. All elective
medical admissions, with the exception
of GIMs C & D and patients of Drs.
Mishriki, Kelly, Levy, and Karess,
should be directed to Cedar Crest &
1-78.

A recent violation received from the
Bureau of Quality Assurance included
the fact that alterations on the records
are not corrected appropriately. Please
be aware that the correct method for
correcting errors on the record is to
draw a line through the incorrect entry,
write "error," date and initial.

Urgent and emergent medical
admissions should be directed to the
emergency department at the facility
where inpatient medical/surgical beds
are available. Facility medical/surgical
bed availability information is
continuously available by calling
402-1875.
Psychiatric, obstetric, pediatric, and
surgical patient services will continue
at present at 17th & Chew.
If you have any questions or concerns,
please contact Mary Agnes Fox,
Administrator, Patient Care Services,
at 402-2285, or Kate Quinn O'Hara,
Administrator, Patient Care Services,
at 402-8210.

Currently, guidelines have not been
established whereby Attestations and
Transcription reports can be signed
electronically. Attestations must bear
the original signature of the physician
who has treated the patient.
Attestations and Transcription reports
which have on-line verification will not
be acceptable and physicians will be
requested to sign a paper copy.
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Intrarectal Ultrasonography Now Available
The John and Dorothy Morgan Cancer
Center is pleased to announce the
availability of a new modality for the
evaluation of anorectal disorders.
Intrarectal ultrasonop-apby is used
pre-operatively to determine the depth
of penetration of rectal tumors and to
evaluate the possible involvement of
regional lymph nodes. In addition,
intrarectal ultrasonography is valuable
for evaluating recurrent pelvic disease.
Lymph node biopsy through the
ultrasound probe is feasible.
This technique may also be applied to
the evaluation of benign diseases of the
anorectum. It can be used to evaluate
the sphincter mechanism in patients
with incontinence, particularly in postpartum women. For complex anorectal
problems, including fistula-in-ano and
intersphincteric abscesses, the

application of this device has been
shown to be valuable.
With the availability of this procedure,
in conjunction with other diagnostic
tests, one can tailor the operative
management to the extent of the
disease. Thus, radical surgery with the
creation of a permanent stoma may be
avoided with the possibility of local
excision affording the same cure.
The intrarectal ultrasound is located in
the G.I. Laboratory at Cedar Crest &
1-78. For more information, please
contact lndru T. Khubchandani, M.D.,
Colon/Rectal Unit Director, John and
Dorothy Morgan Cancer Center, at
402-0500. To schedule a patient for
this procedure, please contact the G.I.
Laboratory at 402-8850.

New Liquid Oxygen System
If you have any questions or need

On Monday, March 28, the
Respiratory Services Department will
implement a new oxygen system which
will be used in the transport and
transfer of patients at the Cedar Crest
& 1-78 site only.

further information, please contact
Wally Smith, Respiratory Equipment
Specialist, at 402-8055.

The new oxygen system utilizes liquid
0 2 portables (LOX). This system
contains more oxygen under less
pressure than the traditional ~
cylinder. In addition, it has a selfcontained regulator and flow meter,
and the LOX portable is refillable.
CAUTION-- As this is a liquid, the
LOX portables must remain upright at

)

aU times.
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New Area Code Change Affects Cellular Telephones
)

As you know, in January, a significant
portion of Pennsylvania received a new
area code. In addition to home and
office telephones, the area code change
has also affected cellular telephones.
Cellular telephones mst be physically
programmed with the new 610 area
code. Depending on the type of
cellular telephone you have,
reprogramming may take only a few
minutes. Failure to have this done by
December 31, 1994, will result in the
loss of service to your cellular
telephone.
As a convenience to physician and
employee users on the HealthPage
Plan, the CellularOne reprogramming
team will visit both sites of Lehigh
Valley Hospital on the following dates

to re-program your cellular telephones
at your convenience and at no charge:
March 21-25

8:30a.m. to 4:30p.m.
March 28-April 1

8:30 a.m. to 4:30 p.m.
At Cedar Crest & 1-78, the
CellularOne van will be stationed in or
near the Physicians' Parking Lot. At
17th & Chew, the CellularOne van will
be stationed in the Visitors' Parking
Lot somewhere between First Fidelity
Bank and the parking deck of the
Fairgrounds Medical Center. If you are
not available during any of these times,
please call the reprogramming team at
390-6113 to schedule an alternate time.

Research Advisory Committee - Request for Proposals
The Research Advisory Committee
(RAC) meets bi-monthly to review
clinical/epidemiological research
proposals (requests for funding)
submitted by the medical and
professional staff of Lehigh Valley
Hospital. All proposals must be
submitted to the Research Department
for review three weeks before the next
scheduled RAC meeting. The next
meeting of the RAC is April20. All
proposals submitted by April 1 will be
reviewed by the Research Department
before being placed on the RAC

For more information and/or proposal
guidelines, contact James F. Reed ill,
Ph.D., Director of Research, at
402-8889.

agenda.
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Library News
New acquisitions to the Health Sciences
Library at Cedar Crest & 1-78 include:
• Baum. Marketing Your Clinical Practice:
Ethically, Effectively, Economically. Aspen
Publishers, 1992.

• Harrison. Harrison's Principles of
Internal Medicine. 13th ed. McGraw Hill,
1994.
• The Of(icial ABMS Diretory of Board
Certiraecl Medical Specialists. 26th ed. Reed
Reference Publishing, 1993.

New acquisitions at 17th & Chew include:
• Avery. Neonatology. 4th ed. J.B.
Lippincott, 1994.
• Creasy. Maternal Fetal Medicine. 3rd ed.
W.B. Saunders, 1994.
• Jackson. Primary Care of tbe Child with
a Chronic Condition. Mosby-Year Book,

+ Physicians routinely receive
advertisements for new_ books. Please
forward recommendations for new library
purchases to the Library Director at Cedar
Crest & 1-78. Your assistance in helping
to maintain a current/relevant book
collection is appreciated.
+ The library utilizes Rittenhouse as its
book jobber. As a convenience,
physicians may also order medical books
for personal use through Rittenhouse. For
a book order form· and instructions or for
more information, call the Health Sciences
Library at 402-8410 (Cedar Crest & 1-78)
or 402-2263 (17th & Chew).

1992.

LVAHEC Annual Category 1 CME Letter
Accreditation for Continuing Medical
Education (CME) in the Lehigh Valley is
undertaken by the Lehigh Valley Area
Health Education Center (LVAHEC).
LV AHEC accredits programs for Lehigh
Valley Hospital, Sacred Heart Hospital,
Quakertown Community Hospital, Easton
Hospital, St. Luke's Hospital, Muhlenberg
Hospital Center, Carbon County Medical
Society, and Allentown Osteopathic
Medical Center (for allopathic accredited
programs).
Each March, LVAHEC compiles and
mails a letter to all physicians listing the
programs attended at its member
institutions during the past calendar year.
This letter serves as documentation for
reporting to the American Medical
Association Physician's Recognition Award
and for documenting CME credits to your
insurance carrier.

Shortly, every Lehigh Valley Hospital
physician who (a) attended programs
approved for CME Category 1 credit, and
(b) had the program director report
attendance to LVAHEC, should receive
their letter. This will be your only
documentation. There is a fee for
replacement letters.
Category 2 credit may be used for part of
the Physician's Recognition Award;
however, each physician must keep records
of their own Category 2 CME. LVAHEC
does not keep Category 2 attendance
records.
If you wish to apply for the American
Medical Association Physician's
Recognition Award, contact the American
Medical Association for an application at
(312) 464-4672.
)
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Physician Assistance Program
25 Reasons to Take Advantage of the Physician Assistance Program

1.
2.
3.
4.

5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.

Emotional and personality
conflicts on the job.
Money management.
Depression.
An adolescent who is using
drugs or alcohol.
Emotional support in deciding
about appropriate care for
elderly patients.
A child who has a behavioral
problem at home or at school.
Chronic anxiety.
Threatened violence or when
you are the victim of violence.
Feelings of being overwhelmed.
Learning to be less passive and
more assertive.
Clarifying important life
decisions.
Eating disorders.
Grieving the loss of loved ones.
Creatively managing stress.
Feelings of loneliness.
Recognizing a drinking
problem.
Resources for marital
counseling.
Drug dependency or addiction
problems.
Gambling problems.
A change in your energy level.
Resources to call upon when
living with an alcoholic.
Working through a serious
financial problem.
Facing serious physical illness.
If you are a recovering
alcoholic and want help.
Readjusting to a divorce or
separation.

For assistance with problems like
these, contact The Counseling
Program's office at (610) 433-8550 or
800-327-8878, identify yourself ONLY
as a member of the Lehigh Valley
Hospital's Medical Staff (or a family
member) and ask to speak to the
Program Manager, Oliver Neith.
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A recent article published for attorneys who
represent plaintiffs in medical malpractice
cases offered the following advice.

Legal Briefings

The high failure rate of claims against health
care providers that are tried to a verdict can
best be explained by the failure to properly
screen a malpractice case prior to accepting
the referral and pursuing the case. This is
partially accounted for by the tendency of
lawyers to "dabble" in medical malpractice
and, therefore, fail to recognize the
subtleties of what may appear to be
negligence at first blush, but actually is an
acceptable complication of a procedure or an
adverse outcome that occurred without
negligent conduct. Another factor is the
availability of medical experts who will
suggest to the plaintiff attorney that
malpractice has, in fact, occurred. Contrary
to popular opinion, the number of "hired
guns" is actually minimal and the majority of
these experts are physicians who do not
specialize in medical malpractice testimony.
An attorney who decides to pursue these
cases should understand that the jury system
is conservative in general, and highly
conservative in medical negligence. Many
people called for jury duty are health care
patients who like and need their doctors.
They do not want to believe that physicians
and hospitals in the community do not render
quality care. They have also seen and heard
the media reports that physicians do not
deliver babies anymore and that malpractice
judgments significantly drive up health care
costs. The latter statement may not be an
accurate statement, but is certainly believed
widely.
It is also important for the plaintiff's
attorney to understand that the legal "killer"
is causation. The causation issue is
invariably dispositive in cases involving
misdiagnosis. In such cases, the defendant's
failure to make a proper diagnosis is always
evident, retrospectively. The only standardof-care issue is whether the defendant failed
to make a proper differential diagnosis. But
the real issue in diagnosis cases is causation.

This is the litmus test on which the claim
must be challenged repeatedly at the outset.
Consider these examples:
• A 54 year-old woman is diagnosed with
cancer of the left breast. During surgery,
the doctor discovers two tumors; 15 lymph
nodes out of 24 test positive for cancer. The
disease is categorized as Stage ll.
The patient had felt one of the tumors 12
months earlier, a fact documented in the
examining physician's records. He told her
not to worry in view of the fact that a
screening mammogram conducted six months
before had been normal.
Sure sounds like clear negligence. Now
consider this - even if the cancer diagnosis
had been made 12 months earlier, the cancer
still would have been categorized as Stage

n.

• A 25 year-old woman with a fever and a
heart murmur is seen by her attending
physician. Instead of being admitted to the
hospital for high-dose intravenous
antibiotics, she is given erythromycin as an
outpatient. After two weeks, her symptoms
have worsened, and she is admitted to the
hospital, where she receives intravenous
antibiotics for bacterial endocarditis.
However, her aortic valve is seriously
damaged and must be replaced.
This case sounds solid. But consider that the
most common complication of bacterial
endocarditis, even when diagnosed early and
treated vigorously, is destruction of the
aortic valve. Valve replacement in this case
would have been likely even if the woman
had been admitted to the hospital
immediately.
If you have any questions regarding this
article or any other legal issues, please
contact the Department of Legal
Services/Risk Management at 402-8201.
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Enteral Formulary Revised
The Enteral Formulary has been
revised with the following changes
being implemented this month.

Clinical

Nutrition News

Replete with Fiber has been added to
the Enteral Formulary. Promote has
been added and will replace Nitrolan.
Vivonex Plus has been added and will
replace Vivonex TEN. NutriHep has
been added and will replace Travasorb
Hepatic.
Description of New Products

Replete with Fiber - A liquid, high
protein, isotonic formula with 14 gms.
fiber/liter - 1.0 cal/cc and 63 gms.
protein per liter.

Congratulations!
George A. Arangio, M.D., orthopedic
surgeon, has been reappointed as
visiting research scientist in the
Institute for Biomedical Engineering
and Mathematical Biology. His current
research and education projects include
long term evaluation of iliotibial band
replacement for the anterior cruciate
deficient knee and the mathematical
modeling of the foot and ankle in
normal and injured states. Dr.
Arangio collaborates with Professor
Eric Salathe, Ph.D., graduate and
undergraduate students on the above
research projects.

David G. Beckwith, Ph.D.,

)

Administrator and Clinical Director
'
Health Network Laboratories, was reelected Chairman of the Pennsylvania

Promote- A liquid, high protein
isotonic formula with 1. 0 callcc and 62
gms. protein per liter.
NutriHep- A liquid, high calorie
formula for liver disease with an amino
acid composition high in branched
chain amino acids and low in aromatic
amino acids. 1.5 callcc with 40 gms.
protein per liter.

Vivonex Plus - An elemental formula
containing 100% free amino acids with
10 gms. of free glutamine/liter. 1.0
callcc and 45 gms. protein per liter.
A new Enteral Formulary reference
card (purple) is available from Clinical
Nutrition Seivices. For a copy of the
new reference card or for more
information, contact Clinical Nutrition
Services at 402-8313 or 402-8378.

lnV Planning Council and Chairman
of the Bethlehem Board of Health.

Ross N. Futerfas, M.D.,
pulmonologist, was recently notified by
the American Board of Internal
Medicine that he successfully passed
the Critical Care Medicine
Examination and is now certified as a
Diplomate in Critical Care Medicine.
Thomas D. Meade, M.D., orthopedic
surgeon, was recently certified as a
team physician by the American
College of Sports Medicine. Dr.
Meade serves as the orthopedic team
surgeon for Muhlenberg College,
Parkland High School, and Whitehall
High School. Dr. Meade is also the
orthopedic consultant to Cedar Crest
College, Emmaus High School, and 12
additional area high schools.
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Publications, Papers and Presentations
Alan B. Leahey, M.D.,
ophthalmologist, co-authored a paper,
Histopatbolo&ic Flndlnp Following
Corneal Gluing with NButylcyanoacrylate in 26 Patients.
This is to be presented at the
Association for Research in Vision and
Ophthalmology in Sarasota, Fla., in
May. This study looks at
histopathologic changes in the corneal
stroma after application of a tissue
adhesive to the cornea during clinical
trials. The clinical results of the study

were previously reported by Dr.
Leahey in Ophthalmology, Vol. 100,
1993; however, this is the first time
that a large number of clinical cases
have been looked at histopathologically.

Definin& Value: Turning Softer
Issues Into Hard Numbers, an article
written by Donald L. Levick, M.D.,
pediatrician, appeared as the Guest
Editorial in the February 1994 edition
of The Physidan 's Advisory.

Upcoming Semi1UlTS, Conferences and Meetings
Regional Symposium Series V
Update on Heart and Lung Surgery
will be presented on Saturday, March
26, from 7 a.m. to 12:45 p.m., in the
Auditorium of Lehigh Valley Hospital,
Cedar Crest & 1-78.
Physicians, nurses, and other health
care professionals interested in an
update on heart and lung surgery will
benefit from this program.
At the completion of the program,
participants should be able to:
• describe cardiomyoplasty and its use
in various patient populations
• describe the new technique for
artificial replacement of the aortic
valve and arch, and
• describe the indications for using
thoracoscopic surgery as a treatment in
pulmonary and mediastinal disease.

Update: Management of Diabetes in
Chlldren will be presented on
Thursday, April21, from 1 to 4:30
p.m., in the Auditorium of Lehigh
Valley Hospital, Cedai Crest & 1-78.

)

Physicians, family practitioners,
nurses, and other health care
professionals interested in the
management of diabetes in children
will benefit from this program.
At the completion of the program,
participants should be able to:
• describe the outcomes associated
with tight control of diabetes mellitus
in children
• discuss the state-of-the-art
prevention, diagnosis, and treatment of
renal complications in juvenile onset
IDDM.
For more information, please contact
Human Resource Development at
402-4609.

)

Continued on Page 11
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Penn State Continuing
Education
Fetal Alcohol Syndrome/Fetal
Alcohol Effects: Prevention,
Intervention, and Diagnosis will be
presented on Wednesday, April 6, at
the Nittany Lion Inn, State College,
Pa.
Family practitioners, obstetricians/
gynecologists, and pediatricians will
benefit from the program.
For more information, call
(717) 531-7965.
Customer Service Excellence in the
Business of Health Care will be
presented on Wednesday, April20,
from 8:30a.m. to 5 p.m., at the
Holiday Inn East, Harrisburg, Pa.

All healthcare employees having direct
patient or public contact will benefit
from this workshop.
Participants should learn:
• the basic skills of excellent customer
relations service
• critical communication skills for the
public-contactpenwn
• key winning service techniques
• strategies for recognizing and
dealing with different types of
questions
• methods for handling complaints and
anger
• a system for handling stressful
disagreements
• strategies for reaching agreement
)

For more information, call
(717) 531-6596.

Otolaryngic Allergy and
Immunology: The Basics and Beyond
will be presented Friday, May 20
through Wednesday, May 25, at the
Sheraton Station Square, Pittsburgh,
Pa.
This course is for otolaryngologists or
interested primary care physicians
wishing to add allergy to their practice
or to update their knowledge of current
techniques.
For more information, please call
(717) 531-7965.

Medical Grand Rounds
H-Pylori will be presented by Robert
Ganz, M.D., Clinical Instructor of
Medicine, University of Minnesota, on
Tuesday, March 15.
Benip Prostatic Hypertrophy will be
presented by Edward M. Mullin, Jr.,
M.D., urologist, on Tuesday, March
22.
Nousurgical Management of Patients
With Lower Back Pain: The
Noncutting Edge will be presented by
Richard Bonfiglio, M.D., Bryn Mawr
Rehabilitation Hospital, on Tuesday,
March 29.
The above Medical Grand Rounds will
begin at noon in the Auditorium of
Lehigh Valley Hospital, Cedar Crest &
1-78. For more infonnation, contact
the Department of Medicine at
402-8200.

Continued on Page 12
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Department of Pediatrics
Developmental Genetics Screening
will be presented by Roger Ladda,
M.D., Chief, Division of Genetics,
Hershey Medical Center, on Friday,
March 25.
Update of HIV will be presented by
Rick Rutstein, M.D., Medical
Director, Special Immunology Clinic,
Children's Hospital of Philadelphia, on
Friday, April 8.
Pediatric conferences are held at noon
in the Auditorium of Lehigh Valley
Hospital, 17th & Chew. For more
information, contact Beverly
Humphrey in the Department of
Pediatrics at 402-2410.

Psychiatric Grand Rounds
Clinical and Research Advances in
Multiple Personality will be presented
by Marlene Steinberg, M.D., Associate
Research Scientist in the Department of
Psychiatry, Yale University School of
Medicine, New Haven, Conn., on
Thursday, March 17, from noon to 1
p.m., in the Auditorium of Lehigh
Valley Hospital, 17th & Chew.
As lunch will be provided, preregistration is requested by calling the
Department of Psychiatry at 402-2810.

Babysitting Class Offered
Would your babysitter know what to
do if your child swallowed an object
and was choking? Would he or she
know who to call if a fire started in
your kitchen? These and other
questions will be answered during
SuperSitter, a free babysitting class
offered as a public service by Lehigh
Valley Hospital. This program will be
held on Saturday, April 30, from 8:45
a.m. to noon, in the Auditorium of
Lehigh Valley Hospital, 17th & Chew.

SuperSitter is geared toward youths 11
years and older who want information
on becoming a knowledgeable
babysitter. Speaking on various
aspects of safety, emergencies, and
first aid will be members of the
Allentown Police and Fire departments
and an educator from the Lehigh
Valley Poison Center. Some helpful
tips on general infant and toddler care,
how to find babysitting jobs, and the
proper way of communicating with
employers will also be offered by
employees of various hospital
departments.
Certificates and special SuperSitter
notepads will be awarded to all those
who attend the three-hour session. As
space is limited to 100 participants,
early registration is suggested.
Deadline to register is April 22. For
more information or to register, call
WomanCare at 402-3800.
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• For Sale or Lease -Springhouse Professional Center,
1575 Pond Road. Ideal for
physician's office.
Approximately 1,000 sq. ft.
• For Sales or Lease -- Medical/
Professional three-story office
building at 1730 Chew Street,
Allentown. Excellent condition
with recent renovations.
Approximately 6,800 sq. ft. for
single or multiple specialty
practice. Includes long-term
parking lease at Fairgrounds.
Potential telephone and dictations
systems.
• For Sale-- Office building at
Northeast comer of 19th and
Turner Streets in Allentown.
Upper level - 2,400 + sq. ft.,
large waiting room, two large
consultation rooms, five exam
rooms, etc. Lower level 2,300 + sq. ft. Parking lot for 16
cars.
• For Lease -- Office to sublet on
Monday, Tuesday, Thursday, and
Friday. 950 sq. ft. Common
waiting area. Lakeside Professional Building, Quakertown.
• For Lease -- Monday time slot
available in the medical office
building on the campus of
Gnaden Huetten Memorial
Hospital in Lehighton.

)

• For Lease -- Medical/professional office space located on
Route 222 in Wescosville. Two
1,000 sq. ft. offices available or
combine to form larger suite.

• For Lease -- Slots are currently
available for the Brown Bag suite
at Kutztown Professional Center.
Ideal for satellite location.
• For Lease -- Large, newly
remodeled, completely furnished
medical office space available for
subleasing/time share at Cedar
Crest Professional Park. Top of
line telephone system. Transcription and computer system with
electronic billing available.
• For Lease -- Medical office
space located in Peachtree Office
Plaza in Whitehall. One suite
with 1,500 sq. ft. (unfinished allowance available), and one
1,000 sq. ft. finished suite.
• For Lease-- Specialty practice
time-share space available in a
comprehensive health care
facility. Riverside Professional
Center, 4019 Wynnewood Drive,
Laurys Station. Half- or full-day
slots immediately available.
• For Lease -- Professional office
space available in an established
psychology and psychotherapy
practice at 45 North 13th Street,
Allentown. Large, warm
Victorian building in a relaxed
atmosphere. Secretary and
billing available and included in
some leases. Furnished or
unfurnished full offices and
sublets available. Utilities
included.
J

For more information, contact
Joe Pilla, Physician Relations
Rep, at 402-9856.
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WHO'S NEW
The Who's New section of Medictrl Staff
Progress Notes contains an update of new
appointments, address changes, newly
approved privileges, etc. Please remember
that each department or unit is responsible
for updating its directory, rolodexes, and
approved privilege rosters.

Carmine J. Pellosie, DO

Department of Family Practice
Division of Occupational Medicine
from Provisional Courtesy to Provisional
Active

Medical Staff

Cllfford G. Vernick, MD
Department of Surgery
Division of Orthopedic Surgery
Section of Ortho Trauma
From Active to Emeritus Active

Appointments

Brian D. Wilson, MD

J. Stephen Long, MD

Department of Family Practice
From Courtesy to Provisional Active

Trexlertown Medical Center
6802 Hamilton Blvd.
Trexlertown, PA 18087
(610) 395-1924
Department of Family Practice
Provisional Active
Meera V. Pathare, MD

Valley Medical Center
Route 663 & Geryville Pike
P.O. Box 216
Pennsburg, PA 18073
(610) 679-8071
Department of Medicine
Division of General Internal Medicine
Provisional Courtesy

Additional Privileges
John J. Stasik, MD
Department of Surgery
Division of Colon & Rectal Surgery
Active
Intra-Rectal Ultrasound Privileges

Practice Changes
Kevin

J. Glancy, MD

No longer associated with Surgical
Associates of the Lehigh Valley, Inc.

Practice Name Change
The corporate name Robert Kiesel, MD,
PC has changed to Fairgrounds Eye
Associates, PC. The practice includes
Robert Kiesel, MD, & Alan Leahey, MD

Address Change
Kevin

J. Glancy, MD

1210 S. Cedar Crest Blvd.
Suite 3900
Allentown, PA 18103
(610) 402-8445

Allied Health Professionals

Change of Status
Resignation
John B. Longenhagen, MD
Department of Medicine
Division of General Internal Medicine
From Courtesy to Emeritus Courtesy

Donna Strain, MA

Physician Extender
Technical Category - MA
(Dr. Khan)

Martin D. Misenhimer, MD
Department of Pediatrics
Division of General Pediatrics
From Active to Emeritus Active
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P & T Highlights
The following actions were
taken at the February 14, 1994
P & T Committee meeting.
James A. Giardina, R.Ph.,
Director of Pharmacy

FORMULARY ADDITIONS
BREATHING EASIER ..... .
Dornase Alfa (Pulmo:zyme, Genentech)is the newest biotechnology agent
approved in 1993. Dornase Alfa is
indicated in conjunction with standard
therapies in the management of cystic
fibrosis patients to reduce the frequency of
respiratory infections requiring parenteral
antibiotics and to improve pulmonary
function. Dornase Alfa is recombinant
DNase, a glycoprotein, and is thought to
work through selective cleavage of DNA
in purulent secretions in the airway.
Dornase Alfa is given via certain
nebulizers or compressors as an inhalation.
It's onset of action is usually seen in 3
days. -To be effective, Dornase alfa should
be given chronically. The recommended
dose is 2.5 mg daily. Some patients
(study subset analysis suggests pts > 21
years or with FVC > 85% of predicted)
may benefit from twice daily inhalations.
Patients with FVC < 40% of predicted
showed no pulmonary function benefit in
short term use from Dornase Alfa therapy.
Safety & efficacy have not been
demonstrated in pts < 5 years old.

There are no well controlled studies in
pregnant women, and excretion in breast
milk is unknown. Dornase alfa is
contraindicated in patients with known
hypersensitivity to any of its ingredients,
including its derivation source, Chinese
Hamster Ovary cell products. The most
common adverse events include voice
alteration, pharyngitis, laryngitis,
conjunctivitis, chest pain, and rash. In
clinical trials, most reactions were
transient, mild, and did not require dosing
alterations. Few patients (3%)
experienced reactions which required
permanent discontinuation. While no
formal drug interaction studies have been
performed, it appears that Dornase alfa
can be safely and effectively used in
conjunction with standard cystic fibrosis
therapies. It should not be mixed with
other drugs in the same nebulizer.
Dornase alfa inhalation solution must be
refrigerated & protected from strong light.
It should not be exposed to room
temperatures for a total time of 24 hours.

)
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Loratidine (CIIlritin, Schering) is a long
acting antihistamine, classified as a
selective peripheral H1 receptor
antagonist. Loratidine possesses less
potential for CNS effects than earlier
generation antihistamines, and also appears
to have less tendency for adverse cardiac
(Torsades de Pointes) events and drug
interactions than either Terfenadine
(Seldane) or Astemizole (Hismanal). It is
rapidly absorbed following oral
administration and undergoes rapid first
pass metabolism to an active metabolite.
Onset of action occurs within 1 to 3 hours,
reaching a peak in 8 to 12 hours and
lasting longer than 24 hours. Patients with
hepatic impairment have reduced
clearance. Both Loratidine and it's
metabolite are excreted in breast milk.
Loratidine is given as a 10 mg tablet daily
to patients over 12 years of age.
Although peak concentrations are elevated
in renal failure, elimination half lives

appear similar to those in non renal
impaired patients, therefore no dosage
adjustment is recommended by the
manufacturer in these patients. In patients
with hepatic failure, the dose should be
given every other day. Common adverse
events include headache, somnolence,
fatigue & dry mouth. Risks of adverse
effects increase with increased dose (not
recommended), in geriatric patients and in
those with renal or hepatic impairment,
even at usual doses. While no ECG or
adverse effects were noted in limited
studies with ketoconazole or
erythromycin, caution should be used with
these and any other agents known to
impair hepatic metabolism. Loratidine
costs about $1.30/day, which is
comparable to Terfenadine & Astemizole,
yet significantly more than
Chlorpheniramine ($0.12/day). Given that
Loratidine appears to offer several
advantages over Astemizole, Loratidine
was added and Astemizole was deleted
from the formulary.

REVERSING THE SWITCH...
Diltiiu.em CD (Cardizem CD, MMD) is
one of the once daily formulations of this
Calcium Channel Blocker. The Committee
approved adding this formulation to the
Formulary and reversing the substitution
practice of dispensing Diltiazem SR when
either Cardizem CD or Dilacor XR was
ordered. Diltiazem CD comes as 120 mg,
180 mg, 240 mg & 300 mg sustained
·
release capsules. Aside from the once
daily dosing and the different strengths, all
other prescribing information is the same
as with the other Diltiazem formulations.

As with many other sustained release
formulations, these products should not be
crushed. The Committee agreed to the
following:
- Add Diltiazem CD to the Formulary
- Dispense the CD formulation for all
twice daily SR orders and identical
strength Dilacor XR orders
- Dispense the SR formulation for non
twice daily SR orders
- Communicate these changes to the
Prescriber via an Order "per P&T
Policy" in the patient's Medical Record

)
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THERAPEUTIC EVALUATION
Finasteride (Proscar, Merck) &
HydroxypropylmethylceUulose (HPMC)
2% (Occucoat, Storz) had been added to
this category in 1993 to allow for
evaluation prior to consideration for
formulary addition. Finasteride ruis had
consistent use and was added to the
formulary. Note was again made of the
precaution relative to females of child
bearing potential not touching the tablets.

(Pharmacy dispenses each dose with a
caution sticker). On the other hand, the
Committee requested that the
Ophthalmology Division review the role of
HPMC together with Sodium
Hyaluronidate (Healon) and Chondroitin &
Sodium Hyaluronidate (Viscoat) prior to a
decision on formulary status for this agent.

DRUG USE EVALUATION (DUE) CORNER
Target Antibiotics
Overview - December costs were $110,478, which is 2% less than November. Average cost
per gram was also less than November 93 as well as December 92.

Ciprofloxacin - 20 patients receiving IV
ciprofloxacin were reviewed in December.
No cases of surgical prophylaxis were
noted. 14 (70%) cases of empiric therapy
were observed with the average length of
therapy of 3 days. IV to PO conversion

)

memos were placed on 12 of 20 60%)
charts. The remaining 8 cases were either
non applicable for oral therapy or had their
antibiotic regimen changed or D/C'd prior
to review. Of the 12 notes placed only 2
(16.7%) were changed to oral therapy.

Ceftazidime - 48 patients receiving
ceftazidime were reviewed in December.
(Piperacillin therapy was chosen in 83
cases during this month). 64.6% of the
ceftazidime use was empiric with an
average length of therapy of 4.1 days.
Piperacillin conversion notes were non

applicable in all the ceftazidime 2 Gm
cases due to allergy, piperacillin failure, or
therapy discontinuation before our review.
One pan sensitive PSAE UTI received I. V.
ceftazidime therapy for 4 days before it
was changed to oral ciprofloxacin.

AmpiciUin/Sulbactam - 60 patients

with an average LOT of 3.6 days. One
surgical prophylaxis case is noted with
48H of antibiotic therapy post vaginal
hysterectomy. The approved amp/SB
chart memos were begun mid-December.
No data regarding their success is available
as yet.

receiving ampicillinlsulbactam were
reviewed in December. 17 (28.3%) of
cases were being treated for mixed
infections with therapy changed to oral as
soon as feasible in the majority of cases.
38 (63.3%) received amp/SB empirically
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PATCHING CHRONIC PAIN...
Transdennal Fentanyl Usage Criteria
The manufacturer recently included a
boxed warning in the official labelling
stating that serious or life threatening
hypoventilation could occur with
transdermal fentanyl (Duragesic, Janssen)
and that it is contraindicated in the
management of acute or post operative
pain (including outpatient surgery), mild or

intermittent pain manageable by lesser
means, in doses exceeding 25 mcg/hr at
initiation of opioid therapy, and in children
less than 12 or patients under 18 weighing
less than 50 kg except in an authorized
investigational research setting. The
Committee approved the following criteria
for study of transdermal fentanyl usage:

Justification

Chronic pain (pain present 48 hours post op & expected to
last 30 days) uncontrolled by lesser means, which requires
continuous opioid use.

Dosing (initial)

25 mcg/hr if naive to opioids; if receiving opioids, dosing is
based on comparable total daily morphine use.

Dosing (adjustment)

After three days based on supplemental analgesics; subsequent
adjustments should be made every six days.

Contraindications

Pre-existing pulmonary disease.

Complications (presence)

Occurrence of side effects together with management (if
required).

Outcome measure

Documentation of pain relief.

ERRATA, ERRATA
In the last issue of P & T Highlights the
cost of Liothyronine injection 60mcg was

inadvertently stated at $1100/dose. The
correct cost is $185/dose.

)
pt\21494.hi
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Issues In Medical Ethics
Spring 1994

Editorial:
n this second issue of"Issues... " Dr.Stephen Lammers discusses Do-Not-Resuscitate
orders, advance directives and the patient self determination act (PSDA). These
timely and important issues are presendy the subject of a growing debate. Should
cardiopulmonary resuscitation be applied to all patients unless specifically requested?
Are we resuscitating people with no hope of recovery, squandering health care dollars
on a 'futile' activity? Has the PSDA helped patients and families make their wishes
known to hospitals and physicians in the event of a terminal or unrecoverable illness?
Dr.Lammers guides us through these topics with thought provoking insights. Later in
the spring the Ethics Committee will host a debate on Do-Not-Resuscitate orders.
Look for announcements for this upcoming event. In the next issue: "Medical care for
Jehovah's Witnesses."
-AD. Rae-Grant

I

The New "DNR" Debate

Contributing Editors:
A.D. Rae-Grant, M.D.,

F.R.C.P.(C.)
S. Lammers, Ph.d.
) J. Vincent, M.D.
· G. Brunst

Once again, cardiopulmonary resuscitation (CPR) is the topic of contentious discussion in nursing and medicine. This very
powerful and dramatically effective intervention is at the center of what some are
calling a "new'' debate. The occasion of
the new debate is a worry that useless
interventions are being tried and a related
concern about the rising costs of medical
care caused by these useless interventions.
What are the issues?
The first issue concerns the concept of
futility in medical care. What is crucial
here is how one defines "futility." For
some commentators, a procedure is futile
if it has less than a 15% chance of being
effective. For other commentators, a procedure is futile only if the probability of
effectiveness is 0%. These latter commentators are focusing upon what has been
called the "physiological" concept of futility. CPR is not futile under this latter definition of if it restores cardiac function to a

patient in Persistent vegetative state (PVS)
even though it will not restore consciousness to the patient.
Once one has determined how futility
should be defined, and as yet there is no
consensus in the literature, the next issue is
whether CPR should automatically be
given to patients? If the procedure is
"futile", should it even be offered to
patients? Is there any need to involve
patients in a discussion of a therapy which
cannot assist them?
If we extend the analysis however, the
issue of futility and CPR becomes even
more complex. What happens if we take
into account the patient's conception of
futility, so that a patient might think CPR
would be futile if it were unlikely to
restore the patient to a level of functioning
desired by the patient? Thus we could
have a siruation in which CPR might not
Continued on Page 2
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be physiologically "futile" but would be
"futile" in terms of the outcome desired by
the patient and projected by the physician.
A recent paper Gecker and Schneiderman, 1993) has suggested that a physiological definition of futility (a procedure is
"futile" if and only if the probability of
benefit is 0%) might set too high a standard but that there is a way for medical
professionals to set a "patient centered"
standard. In contrast to the physiological
standard, physicians would be allowed to
withdraw treatments, including CPR, not
only when the probability of benefit is 0%,
but when the quality of benefit falls below
a certain minimal standard. One way to
judge this is to ask whether the proposed
treatment benefits only a failing organ or
benefits the patient. In cases where there is
a patient in a persistent vegetative state,
CPR does not, in the opinion of these
authors, benefit the patient. What remains
in dispute is the process of consultation
the physician would have to go through in
order to do this.
This new debate also has made it clear
that there are some issues which were not
settled in previous discussions of CPR and
DNR orders. For some physicians and
nurses, a DNR order is compatible with
aggressive care; for others, a DNR order is
a signal that one has "given up" on trying
to cure the patient and one has begun the
process of care that will lead to the patient's death. In fact, the ethical stan~ard here
is clear. DNR orders are compatible with
aggressive care and should not be interpreted, by themselves, as evidence that
other treatments should be withdrawn. Of
course, a DNR order may be part of a care
plan for a patient that will include "cornfort measures only"' but there is no necessary connection between DNR orders and
comfort care.
The new debate has also made it clear
once again that different physicians have
soikingly different understandings of what
is being withheld if a DNR order is written. For some, it means all attempts at
resuscitation; for others, it means only

those resuscitative measures supported by
a code team. In this hospital, DNR indicates that the hospital code team will not
be called in the event of a cardiac, pulmonary or cardiopulmonary arrest. Further, DNR also means that intubation and
ventilation will not be initiated, there will
be no closed cardiac massage, and no
emergency medications will be given.
Perhaps the most interesting proposal
thus far questions whether CPR should
have the status which it has in modern
medicine. DNR orders are quite unusual
in one sense, in that the usual hospital protocol is that whatever is going to be done
must be ordered by a responsible party.
There are always emergency exceptions to
matters but the norm is that orders must
be given before care is to be rendered.
This is not true of CPR. It is done without
an order and is withheld only if an order to
withhold is given. CPR has become so
much a part of the functioning of a modern hospital that we rarely give this a second thought. The point here is not that
this is necessarily irrational. If nurses had
to wait for orders in many situations, the
patient that could have been helped will
have died. The point is that CPR is different and the difference should be noted.
Indeed, in the literature on nursing
homes, one of the proposals is that CPR
not be the norm, but should be given only
if there is a physician's order that CPR is
appropriate for this particular patient. The
norm would be that DNR would be standard for all nursing home residents and
CPR would be given only if it was directed.
I am not taking a position here on this
proposal, but the existence of the proposal
does indicate that there is some attention
to the status of CPR. The issue is being
raised about classes of cases where the
norm would not be "DO CPR!!" but the
norm would be, "In cases like this one, we
do CPR only if it is ordered". What sorts
of cases these might be bring us back to
the first discussion above.
Continued on Page 3
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For example, there are cases in which
CPR is not known to have any benefit to a
patient if benefit is measured as "being discharged alive". When such cases arise, the
question is, should the standard of care be,
"DO CPR!"? Perhaps the standard should
be, "DO CPR ONLY IF IT IS
ORDERED!" Patients could and should
still be approached, so the argument goes,
but the information that would be given
would include the prognosis of death even
if they survived CPR. In such a circumstance, the question, "Do you want us to
do. everything?" is entirely inappropriate.
Better here, and elsewhere, is the following: "How do you want us to care for you?
Let me tell you what we might do and
what are the probable outcomes. Then let
us discuss what you would like done".
All this will not be easy, of course. In
part it will not be easy because physicians
may fear not offering and not doing everything for patients, when "everything" is
defined and described as high technology
interventions. In part it is because we have
radically undercut physician moral authority in our society so that the physician
might discuss with us how we might be
appropriately cared for, instead of being
only technologically assisted. We have
confused "medical care" with "technological assistance". Nor does refusal of technological assistance mean, "Doing nothing''.
It may include all sorts of comfort care
measures.
In part it is difficult because Americans
continue to perpetuate a death denying
attitude which makes it difficult to discuss
these matters. Thus they submit themselves to interventions such as CPR
because they are unwilling to admit that
there is a "time to die".
It has been suggested that the new
DNR debate began for the wrong reasons,
that it might be driven by worries about
the cost of health care. In truth, this
charge may be true. But whatever the reason for which it began, it offers the opportunity to be clearer about the limits of
medical care and what is appropriate when

the limits on one kind of care are reached
and another kind of care should begin. As
confusing and as contentious as the debate
might be, in that aspect at least, it is an
opportunity for physicians and nurses to
have conversations with their patients
about what is important to them, and
about the limits of the practices of nursing
and medicine. The debate also makes it
clear that values are an integral part of medical practice, and that any choices which
one makes on this issue involves values.
What could help is if we knew more
about CPR in particular contexts, so that
physicians and nurses could better advise
patients. Perhaps the next step in our own
DNR debate would be to find out what we
could about the experience at this hospital.
Any volunteers?
-S.Lammers
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PSDA And Advance Directives:
"What Have We Leam.ed After Two Years?
Over two years ago, hospitals and other
health care providers were required to ask
whether their patients had advance directives and to provide information about
advance directives if the patients desired
that information. The Federal legislation
which mandates this process is called the
Patient Self Determination Act (PSDA)
and the advance directives usually discussed under this legislation include living
wills and durable power of attorney for
healthcare documents. In theory, of
course, any written instruction could be an
"advance directive." Thus organ donation
documents and patient signed DNR
orders might fall into this category. For
purposes of the discussion here, we will
focus only upon living wills and durable
power of attorney for healthcare documents.
The hope was, of course, that by asking
patients whether they had such documents, and offering them information
about advance directives, more patients
would complete such documents and this
would give patients more control over
their medical care. In addition, some persons hoped that more patients would
choose less medical care at the end of their
lives and health care expenditures would
slightly decrease.
Advance directives are now the subject
of much attention in the medical literature. Investigators are curious about
whether they are in fact used and, if they
are used, under what circumstances. They
are investigating what forms of advance
directives are more helpful and which less
helpful. The results of these investigations
are interesting. They give us a look at the
limits of centralized intervention in medical care and they also tell us a lot about the
ethos of medicine today. What do I mean?
It is clear that advance directives are not
being used as often as the proponents of
them wished them to be.

For example, patients are too often
writing advance directives right at the end
of life. The reasons for this are unclear but
what is clear is that patients should formulate advance directives much earlier in
their lives if they are to be helpful to
physicians, nurses, and family members.
Investigators have learned that patients
desire discussions about advance directives
more than physicians desire to discuss the
subject with their patients. Investigators
learned that patients are more likely to
develop useful advance directives if they
participate in an educational process which
includes more than one educational event.
Advance directives which give patients scenarios to which they respond rather than
statements to which they assent or disagree are more helpful, both to physicians
and patients.
One of the consistent findings in study
after study is that surrogates are very often
at odds with the persons for whom they
are supposed to be speaking. It is not simply that surrogates often do not really
know what the person wanted; they often
straightforwardly disagree and do not wish
for the patient what the patient wishes for
her or himself. This finding makes it more
important than ever to discover why surrogates are deciding what they decide in
particular cases. Are they following the
patients wishes or are they substituting
their own wishes for the judgment of the
patient?
All of the above means that those of us
who thought that PSDA would bring in a
new day were mistaken. Now what must
be done is to attend to the issues raised by
the implementation ofPSDA so that better care can be given to patients.
In such a situation, what would seem
like sensible advice to nurses and physicians who have to care for patients? The
Continued on Page 5
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first finding that appears to be consistent is
that physicians ought to be more forthcoming in discussing with patients their
wishes at the end of life. It appears that
patients are much more willing to have
these discussions than physicians believe
and are less frightened by discussions of
death than is widely believed in the medical community. (fhis correlates well with
an old social science finding that incoming
medical students feared death more than
the general population.) ~ving these discussions leads to more clarity about what
patients desire, what are the limits upon
treattnent which they wish to have implemented in their case, and who they wish to
speak for them. One study argues that the
first patient visit is the time to begin.
Having the discussions, of course, is
only the beginning. Physicians and nurses
should realize that they must be careful
with their use of language, since that will
sway patients. It is not that physicians do
not have a role here; that role must be
undertaken responsibly. Secondly, patients
will vacillate on what they wish to be done.
Patients will display here the same uncertainties they display about other aspects of
their medical care.
Part of what is being considered here is
a new direction in medical ethics, which
some are calling "preventive ethics." This
new direction grows out of the commonplace obsetvation that to leave a question
unanswered often causes greater difficulty
later when the primary decision maker, the
patient, is no longer able to answer the
question. If the patient had been sensitively and forthrightly approached, there
would be a much better chance to know
what the patient would have wanted.
Assuming that the patient's wishes did not
ask the physician and the nurses to violate
the law or professional codes, the patient's
wishes could be followed. In this sense,
advance directives are a form of preventive
ethics. They allow all of us who will be
patients an opportunity to reflect on what
we would like done medically as our lives
come to their end and to indicate who

should speak for us when ambiguous circumstances arise.
-S.Lammers
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Advance Directives And PSDA
The following information sheet was
developed by the Ethics Committee. It is
our hope that this will help with the most
asked questions about Advance Directives
andPSDA.
1. What does PSDA mean? PSDA
stands for the "Patient Self Determination
Act." It is a shorthand way of referring to
Federal legislation which applies to all
providers of healthcare.
2. To whom does PSDA apply? The
Patient Self Determination Act applies to
any adult patient admitted to the hospital.
3. What must the hospital do? The
hospital has three immediate obligations
under the law. First, the hospital must
advise the person that they have the right
to make an Advance Directive. Second,
the hospital must ask whether the person
has an Advance Directive. Third, if the
person does not have an Advance Directive, the hospital must inquire if they wish
more information about advance directives
and, most importandy, the hospital must
try to supply that information.
4. Who does these things at LVH?
At Admission, all patients will be provided
with written information. Nursing staff are
responsible for asking if the patient has an
advance directive and, if the patient has
one, for a copy for the chart. Nursing also
asks whether the patient desires more
information.
5. What does Nursing do when it
discovers that a patient wants more
infonnation? Nursing should contact the
PSDA team. They are responsible for seeing the patient and assisting the patient in
any way appropriate. The PSDA team
·consists of patient representatives, chaplains, and clinical social workers.
6. What is an Advance Directive?
An Advance Directive is most often a document which either 1) indicates the
patient's wishes about medical treatment
when the patient can no longer speak for
6

her or himself (Living Will) and/or 2)
indicates who may speak on behalf of the
patient when the patient can no longer
speak for her or himself (Durable Power
of Attorney for Healthcare Decisions).
However, a patient's statement to a physician about how s/he wishes to be treated,
properly documented in the chart, will
also serve as an Advance Directive.
7. Does that mean an Advance
Directive does not apply to a competent patient? That's right! Advance
Directives only go into action when a
patient cannot speak for her or himself; if
the patient can communicate, the patient
should be addressed. To put this another
way: Advance Directives do not determine
medical care for a competent patient.
8. Where would I find a patient's
Advance Directive? A patient's Advance
Directive should be put in the chart, in
front of the Inpatient Face Sheet. IT there
is a DNR order, the Advance Directive
should be placed immediately behind it.
9. Are Advance Directives legal in
Pennsylvania? In April, 1992, Pennsylvania passed legislation making Living Wills
and Durable Power of Attorney for
Healthcare legal documents.
10. 'Who can cancel an Advance
Directive? An Advance Directive may be
cancelled at any time by a competent
patient.
11. Does an Advance Directive
means that a patient should be a
DNR? Not at all! Patients may wish to
have DNR status but the existence of an
Advance Directive implies nothing about
code status.
12. 'Where can I obtain answers to
questions which may arise regarding
Advance.Directives? The patient representatives and the Legal Affuirs department can be used as a resource when questions arise.
-S.Lammers
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NEWSLETTER HEALTH NETWORK LABORATORIES
LABORATORY DIAGNOSIS OF MYOCARDIAL INFARCTION

Myocardial infarction is a medical emergency requiring careful
management of the patient.
In excess of SO% of all deaths associated
with a MI occur within the first 2 hours after the onset of symptoms.
Myocardial infarction is due to the reduction of blood flow {ischemia-energy deficit) which leads to cell death. With cell death comes
increased permeability of the plasma membranes releasing three types
of cellular components: ions {e.g., potassium), metabolites {e.g.
lactate) and macromolecules {e.g. enzymes). All cellular components
are measurable. However, from a laboratory position, the cytoplasmic
enzymes are preferred for the following reasons:
1)

The are readily released from the cell.

2)

They have a finite half life with concentrations amiable to
be measured.

3)

They are easily measured employing "routine" laboratory
techniques with results reportable within 1-2 hours.

Creatine kinase {CK) has been identified as the enzyme of choice. Its
activity in tissue is highest in skeletal muscle followed by cardiac
muscle, brain, intestine, kidney and lung. There are two types of CK
monomers namely muscle {M) and brain {B) . However CK actually exists
as a dimmer and there are 3 ways to combine 2 monomers: MM, MB, BB
known as CK isoenzymes. Skeletal muscle cytoplasmic CK isoenzyme
composition is 98% MM and 2% MB followed by heart at 70% MM and 30% MB
and finally brain which is 100% BB. The other organs are largely BB
with a small amount of MM with almost no MB.
With this background, laboratories utilized the production of CKMB
isoenzyme and total CK activity for the differential diagnosis of a
myocardial infarction from skeletal muscle or other organ damage.
Following a MI the total CK activity and CKMB isoenzyme will peak
{rise and fall) within a 24 hour period. This peaking can be used as
one of three criteria for the diagnosis of a MI.
The other two
criteria are changes in EKG and clinical presentation of the patient.
None of these criteria is 100% sensitive for the diagnosis of a MI but
serial cardiac isoenzymes are 95%, followed by EKG at 70% and finally
clinical presentation such as chest pain at 40%.
For many years we have provided MI profiles that were comprised of
total CK & CK isoenzymes and total LD and LD isoenzymes ordered as a
battery of 3 specimens obtained upon admission, 6-12 hours later and
finally 24-36 hours post admission.
These were offered on a routine
basis, not STAT, and exhibited excellent predictive value.
In response to the changing requirements in delivery of healthcare
services, the laboratory changed its methodology for MI profiles to
include total CK, a very sensitive mass molecule CK-MB measurement and
a specific LDl activity measurement. These tests are offered STAT and
the entire profile is completed within a 16-24 period. These changes
allow for a more rapid diagnosis of the patient either for admission
or discharge.
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In considering a change of methodology for the laboratory diagnosis o_
a MI, the following strategy was developed as guidelines for selection
and subsequent monitoring of this new testing protocol.
1)

Use complementary markers in the cardiac panel
a.
Total CK, MCKMB and LD1.

2)

Select optimal cutoff values for our population
a.
Comparative studies were completed.

3)

Interpretation should consider test combinations not
individual results.
a.
Reference ranges on the reports reflect this concept.

4)

Continuation with sequential sampling.
a.
The ordering of an MI profile of 3 specimens should be
transparent to the physician.

5)

Determine the prevalence of MI in the population.
a.
Low prevalence results in low specificity.

6)

Use Total CK cutoff to indicate CKMB testing.
a.
This criteria has not been instituted at this time.
After experience with the new testing, it will be
proposed that we do not do CKMB testing on patients
with total CK less than some number (for example
75 U/L) .
It is this group of patients that contribute
the most to the false positive result.

Reference ranges for the new testing protocol.
Total CK
10 - 230 u/L
MCKMB
< 5.0 ng/ml
Relative Index < 4.0%
LD1
25 - 70 u/L
The relative index is obtained by dividing the MCKMB value by the
total CK.
It is particularly useful to help differentiate between a
MI and skeletal muscle trauma.
It may not be as useful for those
patients who exhibit a low normal total CK.
It is mandatory, in using
these laboratory values to help in diagnosing a MI, to look at the
serial pattern presentation of the 3 specimens. Depending on the
patients age and sex none of the measured parameters may be above the
reference range.
The elderly, especially females, have lost muscle
mass so that their laboratory values may start very low and never rise
into the abnormal range. Even in these cases the peaking of MCKMB
with increasing LD1, is expected for the diagnosis of MI.
However, the serial presentation of peaking of MCKMB with increasing
LDl, may still be consistent with the diagnosis of MI.

)

It has been brought to the laboratories attention that a number of
patients present with normal to low normal total CK, a slightly
elevated CKMB with an abnormal relative index (RI) and a low LDl.
This presentation does not change for the 3 specimens of the MI
profile. Examples of patient presentations with diagnosis are given
below.
SPECIMEN 3

SPECIMII:N 2

SPECIMEN l

lex

l

MCltMB

_l RI

I LDl

Cit

I MCIDIB I RI

I LDl

I RI

I LDl

I 8.1

16.5

l 59

100

I 8.7

I 8. 7 I 67

145

I 12.8

I 8. n I 73

Cit

I

125

MCltMB

ISCHBMIC HEART DISEASE WITH CRP

Pt. 1

I 88

I 7.1

I 8.1 I 57

113

I 7.6

I 6.7

I 49

UNSTABLE ANGINA WITH CORONARY ARTERY DISEASE

Pt. 2

I 115

I 10.6

I 9.2 I 30

II

119

I 12.1

I 10.1 I 48

ACUTE ANTERIOR WALL MI

Pt. 3

I 178

114.5

I 8.H I 56

201

I 18.6

18.n

I 61

Although the MCKMB is elevated in the first two profiles they do not
exhibit the standard increase-decrease of the total CK and MCKMB. The
relative index is elevated because the total CK is low and the MCKMB
is slightly elevated. These results are usually consistent with a
cardiomyopathy, ischemic heart disease due to coronary insufficiency,
unstable angina, CHF or some combination of the above.
It is often
difficult to differentiate unstable angina from minimum cardiac damage
with these laboratory tests. Some laboratories designate a 9X§Y area
for MCKMB range of 5-8 ng/ml and LDl 70-120 U/L but we have chosen not
to institute this approach at this time.
We will continue to monitor the MI profile results with the following
objectives.
First, do our reference ranges require adjustment?
Secondly, can we increase the diagnostic predictability of the profile
by establishing a cutoff point below which we will not do MCKMB and
LDl measurements? Thirdly, does the LDl measurement help in the
diagnosis of a MI? If it is not clinically useful in the
identification of a prior MI, (occurring > 12 hours prior to
treatment) then should it be offered especially in these times of cost
containment?

John J. Shane, MD
Chairman, Pathology
Editor

)

Gerald E. Clement, Ph.D.
Director, Chemistry
Editor
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